|

Experimental Clinical Trials

4 actively recruiting trials

No change since May 2026

Pipeline

Phase 2: 3Phase 3: 1

Top Sponsors

  • The Third Xiangya Hospital of Central South University1
  • Gruppo Oncologico del Nord-Ovest1
  • First Affiliated Hospital of Zhejiang University1
  • Daewon Pharmaceutical Co., Ltd.1

Indications

  • Cancer3
  • Perennial Allergic Rhinitis Accompanied by Asthma1
  • Sintilimab1
  • Locally Advanced Rectal Cancer (LARC)1
  • Asthma1

Other4 trials

Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
Phase 2
SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer
Phase 2
Study to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With Asthma
Phase 3
The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.